Cell Cycle is a bi-weekly peer-reviewed journal of high priority research from all areas of cell biology. Cell Cycle covers all topics from yeast to man, from DNA to function, from development to aging, from stem cells to cell senescence, from metabolism to cell death, from cancer to neurobiology, from molecular biology to therapeutics. Our goal is fast publication of outstanding research. Cell Cycle has a prominent Editorial Board, which includes 3 Nobel Prize winners and other outstanding scientists. Launched in 2002 by its founding Editor and Editor-in-Chief, Mikhail V. Blagosklonny, Cell Cycle is now one of the largest journals in the field. Once bi-monthly, it is now bi-weekly (7000 papers on PubMed in 2015.) Categories of manuscripts include:Research papers/ReportsPerspectives/ReviewsInvited follow-ups to important articles published in Cell Cycle and elsewhere: Extra Views, Features, News and ViewsCell Cycle offers online manuscript submission and peer-review by independent, anonymous expert referees, as well as a flexible open access policy. The journal is indexed by PubMed/Medline, Thomson Reuters, and Scopus. It is available both in the print and online formats. Cell Cycle will, at the discretion of the Chief Editor, consider reviewer reports from previous submission to other high-impact journals for accelerated review. High-priority papers will be peer-reviewed and published as soon as possible.

《細(xì)胞周期》是一本雙周同行評(píng)審的雜志，內(nèi)容涉及細(xì)胞生物學(xué)各個(gè)領(lǐng)域的重點(diǎn)研究。細(xì)胞周期涵蓋了從酵母到人類(lèi)的所有話題，從DNA到功能，從發(fā)育到衰老，從干細(xì)胞到細(xì)胞衰老，從新陳代謝到細(xì)胞死亡，從癌癥到神經(jīng)生物學(xué)，從分子生物學(xué)到治療學(xué)。我們的目標(biāo)是快速發(fā)表杰出的研究成果。細(xì)胞周期有一個(gè)著名的編輯委員會(huì)，其中包括3位諾貝爾獎(jiǎng)得主和其他杰出的科學(xué)家。《細(xì)胞周期》創(chuàng)刊于2002年，由其創(chuàng)始人兼主編米哈伊爾v布拉戈斯科龍尼(Mikhail V. Blagosklonny)創(chuàng)辦，目前是該領(lǐng)域最大的期刊之一。曾經(jīng)是雙月刊，現(xiàn)在是雙周刊(2015年P(guān)ubMed上有7000篇論文)。手稿類(lèi)別包括:研究論文/報(bào)告觀點(diǎn)/評(píng)論邀請(qǐng)后續(xù)的重要文章發(fā)表在細(xì)胞周期和其他地方:額外的意見(jiàn)，功能，新聞和意見(jiàn)Cell Cycle提供在線稿件提交和由獨(dú)立的匿名專(zhuān)家評(píng)審專(zhuān)家評(píng)審，以及靈活的開(kāi)放獲取政策。該期刊由PubMed/Medline、湯森路透和Scopus編制索引。它有印刷和在線兩種格式。Cell Cycle將根據(jù)主編的決定，考慮以前提交給其他高影響力期刊的審稿人報(bào)告，以便加快審稿速度。優(yōu)先級(jí)高的論文將被同行評(píng)審并盡快發(fā)表。